Co-infection of COVID-19 patients with atypical bacteria: A study based in Jordan

Objective: The aim of this work was to know the prevalence of Chlamydophila pneumoniae and Mycoplasma pneumoniae in coronavirus disease 2019 (COVID-19) patients in Jordan. Also, to assess a TaqMan real-time polymerase chain reaction (PCR) assay in detecting these two bacteria. Methods: This is a retrospective study performed over the last five months of the 2021. All nasopharyngeal specimens from COVID-19 patients were tested for C. pneumonia, and M. pneumoniae. The C. pneumoniae Pst-1 gene and M. pneumoniae P1 cytadhesin protein gene were the targets. Results: In this study, 14 out of 175 individuals with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (8.0%) were co-infected with C. pneumoniae or M. pneumoniae. Co-infection with SARS-CoV-2 and C. pneumoniae was reported in 5 (2.9%) patients, while 9 (5.1%) patients had M. pneumoniae and SARS-CoV-2 co-infection. The mean (± std) of the correlation coefficient of the calibration curve for real-time PCR analysis was –0.993 (± 0.001) for C. pneumoniae and –0.994 (± 0.003) for M. pneumoniae. The mean amplification efficiencies of C. pneumoniae and M. Pneumoniae were 187.62% and 136.86%, respectively. Conclusion: In this first study based in Jordan, patients infected with COVID-19 have a low rate of atypical bacterial co-infection. However, clinicians should suspect co-infections with both common and uncommon bacteria in COVID-19 patients. Large prospective investigations are needed to give additional insight on the true prevalence of these co-infections and their impact on the clinical course of COVID-19 patients.

[1]  Safa Daoud,et al.  The first detection of Pneumocystis jirovecii in asthmatic patients post-COVID-19 in Jordan , 2022, Bosnian journal of basic medical sciences.

[2]  M. Zihlif,et al.  Investigating the human rhinovirus co-infection in patients with asthma exacerbations and COVID-19 , 2022, Pharmacy practice.

[3]  H. Abazid,et al.  Patterns of antibiotic use, knowledge, and perceptions among different population categories: A comprehensive study based in Arabic countries , 2022, Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society.

[4]  N. Verma,et al.  Atypical bacterial co‐infections among patients with COVID‐19: A study from India , 2021, Journal of medical virology.

[5]  B. Gärtner,et al.  Acute Respiratory Distress Syndrome due to Mycoplasma pneumoniae Misinterpreted as SARS-CoV-2 Infection , 2021, Case reports in pulmonology.

[6]  P. Feustel,et al.  Incidence and risk factors for secondary pulmonary infections in patients hospitalized with coronavirus disease 2019 pneumonia , 2021, The American Journal of the Medical Sciences.

[7]  W. Chong,et al.  Incidence, diagnosis and outcomes of COVID-19-associated pulmonary aspergillosis (CAPA): a systematic review , 2021, Journal of Hospital Infection.

[8]  B. Saha,et al.  State-of-the-art review of secondary pulmonary infections in patients with COVID-19 pneumonia , 2021, Infection.

[9]  S. Bhatnagar,et al.  Mycoplasma pneumoniae co-infection with SARS-CoV-2: A case report , 2021, Access microbiology.

[10]  Abhinav Choubey,et al.  Retrospective review analysis of COVID-19 patients co-infected with Mycoplasma pneumoniae , 2021, Lung India.

[11]  A. Alsayed,et al.  Influences of bovine colostrum on nasal swab microbiome and viral upper respiratory tract infections – A case report , 2020, Respiratory Medicine Case Reports.

[12]  Xuedong Zhou,et al.  The microbial coinfection in COVID-19 , 2020, Applied Microbiology and Biotechnology.

[13]  L. Calza,et al.  COVID-19 in patients with HIV-1 infection: a single-centre experience in northern Italy , 2020, Infection.

[14]  P. Palange,et al.  Co-infection of SARS-CoV-2 with Chlamydia or Mycoplasma pneumoniae: a case series and review of the literature , 2020, Infection.

[15]  Sreedhar Adapa,et al.  Presenting characteristics, comorbidities, and outcomes of patients coinfected with COVID‐19 and Mycoplasma pneumoniae in the USA , 2020, Journal of medical virology.

[16]  Jianguo Wu,et al.  Epidemiological and Clinical Characteristics of Patients With Coronavirus Disease-2019 in Shiyan City, China , 2020, Frontiers in Cellular and Infection Microbiology.

[17]  Y. Hu,et al.  Hospitalization and Critical Care of 109 Decedents with COVID-19 Pneumonia in Wuhan, China , 2020, Annals of the American Thoracic Society.

[18]  Y. Xiong,et al.  Clinical features and treatment of COVID‐19 patients in northeast Chongqing , 2020, Journal of medical virology.

[19]  Rui-guang Zhang,et al.  Clinical Features of 69 Cases with Coronavirus Disease 2019 in Wuhan, China , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  Xin Zhou,et al.  Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China , 2020, The Journal of Emergency Medicine.

[21]  Xuehua Peng,et al.  Clinical and CT features in pediatric patients with COVID‐19 infection: Different points from adults , 2020, Pediatric pulmonology.

[22]  B. Grant,et al.  Bacterial colonization increases daily symptoms in patients with chronic obstructive pulmonary disease. , 2014, Annals of the American Thoracic Society.

[23]  N. Shindo,et al.  Bacterial and viral infections associated with influenza , 2013, Influenza and other respiratory viruses.

[24]  T. Murphy,et al.  Infection in the pathogenesis and course of chronic obstructive pulmonary disease. , 2008, The New England journal of medicine.

[25]  D. Murdoch,et al.  Molecular genetic methods in the diagnosis of lower respiratory tract infections , 2004, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.